Page 460«..1020..459460461462..470480..»

"Becky’s" Stem Cell Therapy Story – Video

By raymumme

"Becky" recently had stem cell therapy at Western Veterinary Clinic in South Bend, IN. This is a video about her story.

Read more from the original source:
"Becky's" Stem Cell Therapy Story - Video

To Read More: "Becky’s" Stem Cell Therapy Story – Video
categoriaUncategorized commentoComments Off on "Becky’s" Stem Cell Therapy Story – Video | dataDecember 6th, 2011
Read All

Hopes Dashed That Vitamin D Reduces Cancer Risk

By Dr. Matthew Watson

(HealthDay News) -- New research appears to dash hopes that people who consume more vitamin D might be at less risk of developing several less-common types of cancer.

Researchers found no link between higher blood levels of vitamin D and lower rates of non-Hodgkin lymphoma or cancers of the endometrium, esophagus, stomach, kidney, ovary and pancreas.

Vitamin D is obtained by the body through exposure to sunlight, certain foods such as oily fish, fortified foods and nutritional supplements.

Authors of a new study analyzed blood samples drawn from more than 12,000 men and women in 10 studies. The previous studies followed the patients for as long as 33 years, allowing researchers to determine if they developed cancer.

"We did not see lower cancer risk in persons with high vitamin D blood concentrations compared to normal concentrations for any of these cancers," said study co-investigator Dr. Demetrius Albanes of the U.S. National Cancer Institute in an institute news release. "And, at the other end of the vitamin D spectrum, we did not see higher cancer risk for participants with low levels."

However, the researchers did find that people with high levels of vitamin D were more likely to develop pancreatic cancer. It's not clear if there's a cause-and-effect relationship, and the study authors called for more research to assess the possible association. Read more...

Immunice for Immune Support

Source:
http://feeds.feedburner.com/integratedmedicine

To Read More: Hopes Dashed That Vitamin D Reduces Cancer Risk
categoriaIntegrative Medicine commentoComments Off on Hopes Dashed That Vitamin D Reduces Cancer Risk | dataDecember 4th, 2011
Read All

International Stem Cell Corporation to Present at the 4th Annual LD MICRO Growth Conference on December 8th

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCO) today announced that Co-Chairman Ken Aldrich and President and Chief Operating Officer Kurt May will be presenting at the 4th Annual LD MICRO Growth Conference in Los Angeles on Thursday, December 8, 2011 at 2:30 p.m. Pacific. The conference is being held at the Luxe Sunset Boulevard Hotel.

LD Micro founder Chris Lahiji stated, "We are excited to host over 100 companies for the first time in our history. What makes us especially proud, however, are all the interesting companies from our own backyard in Southern California, such as International Stem Cell, that are presenting this year."

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com

or
LHA
Don Markley
310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

To Read More: International Stem Cell Corporation to Present at the 4th Annual LD MICRO Growth Conference on December 8th
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation to Present at the 4th Annual LD MICRO Growth Conference on December 8th | dataDecember 4th, 2011
Read All

International Stem Cell Corporation to Present Immune Matching Research Advances at Cell Science and Stem Cell Research 2011 Conference

By Dr. Matthew Watson

Executives from International Stem Cell Corporation (OTCBB:ISCO), a biotechnology company specializing in the research and development of stem cell-based therapies, will be presenting advances made in its research programs related to the use of immune-matched patient-specific parthenogenetic stem cells for neurological applications and genetic liver diseases at Cell Science 2011 in Philadelphia on November 29th.

Vice President Ruslan Semechkin, Ph.D., will open the conference and discuss the latest trends in the use of stem cells to treat diseases of the central nervous system. A follow-on presentation will demonstrate that functional dopaminergic neurons can be successfully obtained from human parthenogenetic stem cells. Alina Ostrowska, Ph.D., the Company's Director of Translational Research, will present a new method of obtaining highly-enriched cultures of hepatocyte-like cells from pluripotent human stem cells.

Dr Semechkin comments, "I'm honored to be opening this conference and to be debating the latest advances in stem cell therapies. ISCO will also be presenting the most recent results from two of our most important research programs, where we continue to further characterize our parthenogenetic stem cell lines and their ability to form functioning liver-like cell and functioning neuron-like cells."
ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human pluripotent stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals. ISCO maintains the world's largest collection of research-grade hpSC lines.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20111129005524r1&sid=14230&distro=ftp
International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com

Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

To Read More: International Stem Cell Corporation to Present Immune Matching Research Advances at Cell Science and Stem Cell Research 2011 Conference
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation to Present Immune Matching Research Advances at Cell Science and Stem Cell Research 2011 Conference | dataDecember 4th, 2011
Read All

LifeLine Skin Care’s Holiday Gift Special PLUS an Autographed Copy of John Mauldin’s “Endgame”

By Dr. Matthew Watson

Happy Holidays from Lifeline Skin Care and John Mauldin!

Check Out LifeLine Skin Care’s Holiday Gift Special PLUS an Autographed Copy of John Mauldin’s “Endgame”
• Lifeline Defensive Day Moisture Serum (1 oz.)
• Lifeline Recovery Night Moisture Serum (1 oz.)
• In a beautiful Signature Gift Box
• An original, autographed copy of John Mauldin's newest book, Endgame
Specially priced at $310 ($368+ value!)
Plus Free Shipping to US addresses only*
The Lifeline gift box will ship on or before December 9; the autographed book will ship separately within six weeks of receipt of order.
Or call Customer Service: 1-877-764-9707
Monday-Friday | 9 am-5 pm PST
*International orders can be shipped via USPS Priority Mail for an additional $25. Depending on the destination, order date and Customs clearance, delivery can take from 5-30 days. Exact delivery date cannot be guaranteed.
©2011 Lifeline Skin Care. All Rights Reserved.
Lifeline Skin Care | 5950 Priestly Dr. | Carlsbad, California 92008 | United States



Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

To Read More: LifeLine Skin Care’s Holiday Gift Special PLUS an Autographed Copy of John Mauldin’s “Endgame”
categoriaStem Cell Therapy commentoComments Off on LifeLine Skin Care’s Holiday Gift Special PLUS an Autographed Copy of John Mauldin’s “Endgame” | dataDecember 4th, 2011
Read All

Strategy at CIRM: New Sources of Cash, More Funding Transparency, Better PR?

By Dr. Matthew Watson


The California stem cell agency is huddling with industry, scientists and public as it wades through a revision of its strategic plan to determine how to spend its remaining $1.4 billion before the cash runs out.

CIRM officials have held at least 10 meetings with a variety of groups, including three public sessions. The next public hearing is Thursday in Los Angeles at the CIRM board meeting.

The revision comes as the agency wrestles with the increasing need to generate results that will resonate with California voters. CIRM's original $3 billion, which consists of cash borrowed by the state, will run out in roughly 2017. The agency is considering mounting a ballot campaign for another multibillion dollar bond measure. The agency is also under examination by the prestiguous Institute of Medicine and is likely to hear recommendations for changes from that report next fall.

Ellen Feigal, senior vice president for research and development, summarized stakeholder comments so far on CIRM's plans in a 13-page documment prepared for the meeting at Cedars-Sinai. She identified several key themes from stakeholders, including the need to find "alternate funding resources," presumably non-public financing. Feigal also cited a need to make the grant funding process more transparent, apparently reflecting complaints from industry. But she noted that stakeholders have said the agency has made "great initial progress" in its first seven years.

Here are four of the five themes Feigal identified. The fifth dealt mentioned CIRM's progress.

  • "CIRM needs to become more aggressive in finding alternate funding resources and to implement greater creativity in identifying the types of organizations that may be able to contribute to the sustainability of CIRM's work"
  • "Robust public affairs tactics are necessary, and CIRM needs to better communicate the organizational initiatives, as well as educate the public more broadly."
  • "Greater transparency in the funding process is needed, and there is a great need for the process to be less bureaucratic and easier to navigate."
  • "CIRM needs to provide greater opportunities for networking and breed collaborative projects that unite academic and industry as well as researchers across geographic reasons."

Feigal also mentioned a number of recommendations from industry, which has been less than happy with its meager share of CIRM funding. The suggestions included creation of "communications bridges" and better communication of the funding process. Also recommended was a "split review process – (academic vs. industry)" and a faster approval process that takes into account the high "burn rate" of cash at biotech companies. Another industry suggestion was creation of an "in-house champion" to help businesses navigate the CIRM funding process.

Feigal will come back to the board in January with a draft revision. It is scheduled to be approved March 21. The final plan will be shipped off to the IOM panel studying CIRM. It is scheduled to conclude its work next fall.

Interested parties can email their comments on the plan to CIRM (info@cirm.ca.gov) or speak at CIRM board meetings. The specific address for Thursday's meeting can be found on the agenda. A teleconference location is also available at UC San Francisco, where members of public can take part.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Strategy at CIRM: New Sources of Cash, More Funding Transparency, Better PR?
categoriaStem Cell Therapy commentoComments Off on Strategy at CIRM: New Sources of Cash, More Funding Transparency, Better PR? | dataDecember 4th, 2011
Read All

Luring Stem Cell Researchers to California: A $5.6 Million Bid

By Dr. Matthew Watson


The $3 billion California stem cell agency has played a role in bringing two star researchers to the Golden State through its $44 million recruitment program and is about ready to bring in a third.

Next Thursday in Los Angeles, CIRM's governing board is expected to approve a $5.6 million grant to an unidentified scientist to lure him or her to an unidentified California institution.

The funds will go for the researcher's efforts to develop "a regeneration-based functional restoration treatment for spinal cord injury," according to a summary of reviewer comments on the CIRM web site. The grant was scored at 86 by scientific reviewers.

The summary quoted the researcher as saying,

"We recently made breakthrough discoveries in identifying key biological mechanisms stimulating the re-growth of injured axons in the adult nervous system, which led to unprecedented extents of axon regeneration in various CNS injury models. While our success was compelling, we found that many regenerated axons were stalled at the lesion sites by the injury-induced glial scars. Furthermore, it is unclear whether the regenerated axons can form functional synaptic connections when they grow into the denervated spinal cord. This proposed research program is aimed at solving these obstacles by using human stem cell technologies."

The summary said,

"The PI was described by reviewers as a superb scientist and emerging leader with outstanding accomplishments and exceptional promise. The candidate has already made key contributions to the understanding of mechanism underlying axonal regeneration that have significantly advanced the field of neuroregeneration. He/she has been extremely productive, publishing a number of seminal papers in the highest profile journals including Science, Nature, Neuron and Nature Neuroscience."

The stem cell agency's recruitment efforts have helped to bring Peter Coffey ($4.9 million from CIRM)from the UK to UC Santa Barbara and Robert Wechsler-Reya ($6 million)- to Sanford Burnham in La Jolla from Duke University.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Luring Stem Cell Researchers to California: A $5.6 Million Bid
categoriaStem Cell Therapy commentoComments Off on Luring Stem Cell Researchers to California: A $5.6 Million Bid | dataDecember 4th, 2011
Read All

California Stem Cell Agency and Geron: Ethical Issues with Sales of hESC Trial

By Dr. Matthew Watson


A Canadian bioethicist is raising ethical questions about Geron's hESC trial that have implications for the attempt by the California stem cell agency to salvage the once-vaunted effort.

Writing yesterday on the Hastings Center Bioethics Forum, Francoise Baylis of Dalhousie University said,

"It is one thing to close a trial to further enrollment for scientific reasons, such as a problem with trial design, or for ethical reasons, such as an unanticipated serious risk of harm to participants. It is quite another matter to close a trial for business reasons, such as to improve profit margins."

Geron last month said it was ending the trial because of financial reasons and to pursue development of its cancer treatments. CIRM awarded Geron a $25 million loan just last May and was surprised by the Geron move. The $3 billion state research program is now attempting to find a buyer/partner for Geron's hESC business.

Baylis noted that Stephen Kelsey, chief medical officer of the Menlo Park, Ca., firm, has been quoted as saying that the results of Geron trial – now with five patients instead of the projected 10 – "will be a fair reflection of what would have happened if we had completed the study."

Baylis wrote,

"This statement is deeply problematic, however."

Baylis, a professor and the Canada Research Chair in the departments of philosophy and of obstetrics and gynecology at Dalhousie, continued,

"No clinical trial should involve too few or too many participants. It is important that the trial not be underpowered and thus unable to generate scientific knowledge. It is equally important than no more research participants than necessary be exposed to potential research risks. If only five participants were needed to generate the scientific knowledge, then why would Geron and the F.D.A. have agreed to expose additional persons to the potential harms of trial participation?

"On the other hand, if Kelsey’s statement is false, and the findings from five research participants will be underpowered, then they may have been exposed to the potential harms of trial participation without the potential for benefit in the form of scientific knowledge."

She concluded,

"In either case, the scenario forces us to consider what measures should be taken with respect to future trials funded in the private sector so that participants are not left stranded. Perhaps regulators and institutional review boards should critically examine whether a company has both the financial (and other) resources and the will to complete a trial under review before granting regulatory or ethics approval.  If there are doubts about this, then either the trial should not be approved, or there should be stringent disclosure requirements so that prospective research participants are aware of the possibility that research may stop mid-trial for financial reasons."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: California Stem Cell Agency and Geron: Ethical Issues with Sales of hESC Trial
categoriaStem Cell Therapy commentoComments Off on California Stem Cell Agency and Geron: Ethical Issues with Sales of hESC Trial | dataDecember 4th, 2011
Read All

Researcher Alert: CIRM Readying $57 Million in New Opportunities

By Dr. Matthew Watson


The California stem cell agency is proposing to pump $30 million into new research involving reprogrammed adult stem cells and another $27 million into fresh efforts to speed development of clinical therapies.

In a memo prepared for the CIRM directors meeting next week in Los Angeles, the agency's staff said the $30 million effort could generate "disease-in-a-dish models" that "have the potential to make drug discovery faster, more efficient and more personalized to individual patients."

The "disease-in-a-dish" plan was dubbed a "human pluripotent stem cell (hPSC) initiative" by the staff. The goal is to generate high quality stem cell-based tools for use by the researchers and drug developers.

The proposal includes four elements, one of which is collaboration with the NIH to develop cell lines from patients with Huntington’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. No cost was specified on that effort. Also recommended to directors was a $4 million disease line award round, a $16 million core hiPSC derivation round and a $10 million stem cell bank round. The RFAs would go out in May of next year with funding expected early in 2013.

The staff memo on the initiative did not mention human embryonic stem cells, but a spokeswoman for the agency said they were not excluded from the effort.

The other new grant proposals up next week grew out of a recommendations from a blue-ribbon panel that CIRM organized last year to examine its operations. One element in the plan is a $12 million "bridging fund" that would apply only to current CIRM-funded projects in three areas: disease team grants, some early translational projects and clinical development projects. The bridging fund would provide up to $3 million for up to one year for each recipient, if CIRM President Alan Trounson approves the project. Trounson would be assisted in his evaluation by staff and external consultants, if necessary.

The second part of the response to the review panel's finding is an "external innovation initiative" to support collaborative efforts of CIRM grantees to work with teams that CIRM said are "making extraordinary progress outside California."

The $15 million program would provide awards as often as two times a year. The maximum amount on each award was not specified.

Ellen Feigal, CIRM's vice president of research and development, said in a memo to directors that examples of potential projects included collaborative efforts with the NIH and work with the Harvard Stem Cell Institute and its disease-focused programs.

Some of the latest CIRM initiatives are open to biotech businesses. Others are open only to non-profit or academic researchers.

(Editor's note: An earlier version of this item did not include the sentence dealing with human embryonic stem cells.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Researcher Alert: CIRM Readying $57 Million in New Opportunities
categoriaStem Cell Therapy commentoComments Off on Researcher Alert: CIRM Readying $57 Million in New Opportunities | dataDecember 4th, 2011
Read All

Stem Cell Agency Provides Early Access to Multimillion Dollar Proposals Coming Before its Directors

By Dr. Matthew Watson


Could this be a trend?

The California stem cell agency, working under the direction of a new chairman, has once again posted a handsome amount of background material well in advance of its regular board meeting – in this case the Dec. 8 session at Cedars-Sinai in Los Angeles.

For the past several years, the agency has failed to post in a timely fashion important information on many decisions to be made by agency directors, making it virtually impossible for interested parties to plan to attend meetings or prepare thoughtful suggestions or recommend possible changes.

That situation has begun to change under Chairman Jonathan Thomas, a Los Angeles bond financier, who controls the board agenda and who was elected to his post at the end of June. In August, the agency also posted in a timely fashion a healthy dollop of information on matters to come before the board.

For December's meeting, the agenda contains links to information on a proposed $5.6 million recruitment award to lure a star researcher to the Golden State, an update on CIRM's proposed changes in its strategic plan, two new initiatives totalling $27 million that would accelerate progress to the clinic, grant administration changes that could affect the hundreds of CIRM grant recipients and proposed new scientific members for the group that makes the de facto decisions on which scientists receive CIRM cash.

We will have more on the details of all this later, but readers who have a special interest might want to dip in early. All the background information can be found via the agenda, which also says a remote site in San Francisco will be available for participation of those who cannot make it to Los Angeles.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Stem Cell Agency Provides Early Access to Multimillion Dollar Proposals Coming Before its Directors
categoriaStem Cell Therapy commentoComments Off on Stem Cell Agency Provides Early Access to Multimillion Dollar Proposals Coming Before its Directors | dataDecember 4th, 2011
Read All

Hype, Geron and Stem Cell Research: A Hard-eyed View from the North

By Dr. Matthew Watson


From Canada last week came a stem cell "reality check" that pulled together a professional football quarterback, a Yankee baseball pitcher, a Republican presidential hopeful and Geron.

Timothy Caulfield,
U. of Alberta Photo

What do they all have in common? Stem cell therapy, answered Timothy Caulfield, a Canadian academic, writing on the Canadian version of the Huffington Post. Declaring that stem cell treatments are being ballyhooed as a "miracle cure" and "elixir of life," Caulfield wrote,

"But does it actually work? I think not -- at least not yet."

Caulfield is not one of your stereotypical opponents of stem cell research. In fact, he describes himself as a "believer" in the likelihood of development of effective stem cell therapies. Caulfield also springs from a deep academic background. He is research director of the Health Law Institute at the University of Alberta and has published a plethora of scholarly articles related to stem cell research.

Caulfield wrote that Geron's abandonment of hESC research "underscores the cavernous gap between the well-publicized (and completely legitimate) promise of stem cell research and actual, efficacious, therapies."

He said the California company's decision "generated both shock and anger. And for the patients hoping for a near-future cure, it was nothing less than heartbreaking."

Caulfield continued,

"Not only did the company decide to stop this particular trial, it decided to get out of the field of stem cell therapies altogether. So definitive was the decision that Geron gave back millions of public research dollars(to the California stem cell agency)."

Caulfield warned, however,

"We need to be careful not to over-interpret the Geron pull out. This is one company and one trial. There are now a few other clinical experiments in the pipeline (emphasis on a few), such as one to treat a form of blindness. And we must remember that not all things that are called 'stem cell therapies' are the same. "

Caulfield continued with his "reality check,"

"First, ignore the hype. I believe there is little evidence that any of the often advertised stem cell therapies, embryonic or otherwise, work. Yes, there are a handful of decades-old treatments ….

"(Peyton) Manning, (Bartolo) Colon and (Rick)Perry may have had a positive experience (the placebo effect is a powerful thing, after all), but, to date, I believe good clinical evidence simply does not exist.

"Second, despite the hope of many, it isn't going to be easy to make money off stem cell research -- at least with a treatment that is scientifically legitimate, appropriately tested and approved by the relevant regulatory agencies (three characteristics missing from most of the stem cell therapies currently offered in clinics around the world). "Economic growth has often been one of the ways that the huge public investment in stem cell research has been justified. Just a few weeks ago, for example, the UK government announced that it was committing millions in a stem cell research centre with the hope that it will help drive the UK economic recovery.

"But the ability of emerging stem cell technologies to stimulate the economy and create jobs is far from certain. Indeed, economics is the explicit reason for the Geron pull out. The company press release stated that the decision was made after a strategic review of the costs, timelines and 'clinical, manufacturing and regulatory complexities associated' with this kind of research. In other words, stem cell research is not, from the perspective of this company, worth it."

Caulfield concluded,

"I don't mean to be a downer. In fact, I believe that stem cell research holds tremendous potential. I remain fully confident that, one day, therapies will emerge. But the inappropriate hype associated with this area hurts policy debates, leads to unmet expectations, and has the potential to mislead the public about the actual state of the science. The Geron story is a sober reminder that promise is not reality, even in a field as exciting as stem cell research."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Hype, Geron and Stem Cell Research: A Hard-eyed View from the North
categoriaStem Cell Therapy commentoComments Off on Hype, Geron and Stem Cell Research: A Hard-eyed View from the North | dataDecember 4th, 2011
Read All

The CIRM ‘Debt’ to George Bush and Disgraced Korean Researcher

By Dr. Matthew Watson


It was brief but pointed comment on the differences in the stem cell world of 2004 compared to the stem cell world of 2011.

Larry Ebert, a patent attorney, made the remark on his blog, IPBiz. He was writing about an observation on this website that without George Bush and his restrictions on federal hESC research, there would have been no California stem cell agency.

Ebert said,

"IPBiz notes that when the California voters voted Prop. 71 in, scientists thought Huang Woo Suk's work on hESC was real. In 2011, the current state of the art is still not up to what Huang Woo Suk falsely reported in the journal Science. Californiastemcellreport should give Huang Woo Suk some credit for the passage of Prop. 71."

Consider Woo Suk duly credited.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: The CIRM ‘Debt’ to George Bush and Disgraced Korean Researcher
categoriaStem Cell Therapy commentoComments Off on The CIRM ‘Debt’ to George Bush and Disgraced Korean Researcher | dataDecember 4th, 2011
Read All

information about stem cell transplantation (Bone Marrow) With English subtitles – Video

By daniellenierenberg

i'm Ritchie and I have aplastic anemia Have one stem cell transplant I'm all better.

See the original post:
information about stem cell transplantation (Bone Marrow) With English subtitles - Video

To Read More: information about stem cell transplantation (Bone Marrow) With English subtitles – Video
categoriaBone Marrow Stem Cells commentoComments Off on information about stem cell transplantation (Bone Marrow) With English subtitles – Video | dataDecember 3rd, 2011
Read All

Match Maker: Bone Marrow and Stem Cell Donation at USC Norris Comprehensive Cancer Center – Video

By Sykes24Tracey

Kathleen Neves, RN, allogeneic bone marrow transplant coordinator at USC Norris Cancer Hospital, discusses bone marrow and stem cell donation.

Here is the original post:
Match Maker: Bone Marrow and Stem Cell Donation at USC Norris Comprehensive Cancer Center - Video

To Read More: Match Maker: Bone Marrow and Stem Cell Donation at USC Norris Comprehensive Cancer Center – Video
categoriaBone Marrow Stem Cells commentoComments Off on Match Maker: Bone Marrow and Stem Cell Donation at USC Norris Comprehensive Cancer Center – Video | dataDecember 3rd, 2011
Read All

Stem Cell Transplant Program – Video

By LizaAVILA

Meet some of the patients, families, doctors and nurses of Akron Children's Hospital's Stem Cell Transplant Program. The program, which is part of the Showers Family Center for Childhood Cancer and Blood Disorders, provides both autologous and allogeneic stem cell transplants to help restore the healthy stem cells detroyed by chemotherapy or radiation.

See more here:
Stem Cell Transplant Program - Video

To Read More: Stem Cell Transplant Program – Video
categoriaBone Marrow Stem Cells commentoComments Off on Stem Cell Transplant Program – Video | dataDecember 2nd, 2011
Read All

Eyesight and Hearing loss – Stem Cell therapy (English) – Video

By NEVAGiles23

This video, is a testimonial of a patient from Colorado, USA that went to Progencell, for a Stem cell treatment for her neurologic problem affecting her eyesight and hearing loss. Talks about her experience, her trip, the procedure, the outcome and some suggestions.

Read the rest here:
Eyesight and Hearing loss - Stem Cell therapy (English) - Video

To Read More: Eyesight and Hearing loss – Stem Cell therapy (English) – Video
categoriaBone Marrow Stem Cells commentoComments Off on Eyesight and Hearing loss – Stem Cell therapy (English) – Video | dataDecember 2nd, 2011
Read All

Diabetes- Stem cell therapy (english) – Video

By LizaAVILA

This video, is a testimonial of a patient from Florida that went to Progencell, for a Stem cell treatment for his Diabetes. Talks about his experience, his trip, the procedure, the outcome and some suggestions.

Original post:
Diabetes- Stem cell therapy (english) - Video

To Read More: Diabetes- Stem cell therapy (english) – Video
categoriaBone Marrow Stem Cells commentoComments Off on Diabetes- Stem cell therapy (english) – Video | dataDecember 2nd, 2011
Read All

Best Stem Cell Skin Care Products – Video

By Dr. Matthew Watson

Best stem cell skin care products http://www.youtube.com

Read this article:
Best Stem Cell Skin Care Products - Video

To Read More: Best Stem Cell Skin Care Products – Video
categoriaSkin Stem Cells commentoComments Off on Best Stem Cell Skin Care Products – Video | dataDecember 2nd, 2011
Read All

Stem cell vet treatment performed in Ontario – Video

By daniellenierenberg

A seven-year-old black Newfoundland dog has become the first canine in Canada to receive a stem cell operation performed entirely in a veterinary office. The procedure was performed Friday morning by veterinarians Dr.

Read more:
Stem cell vet treatment performed in Ontario - Video

To Read More: Stem cell vet treatment performed in Ontario – Video
categoriaUncategorized commentoComments Off on Stem cell vet treatment performed in Ontario – Video | dataDecember 1st, 2011
Read All

Bradley help with his hips from his doctor who is his owner – Video

By JoanneRUSSELL25

To learn more about stem cell therapy and how its helping pets across the US, Visit: http://www.medivet-america.com

Here is the original post:
Bradley help with his hips from his doctor who is his owner - Video

To Read More: Bradley help with his hips from his doctor who is his owner – Video
categoriaUncategorized commentoComments Off on Bradley help with his hips from his doctor who is his owner – Video | dataDecember 1st, 2011
Read All

Page 460«..1020..459460461462..470480..»